Investors Overview

Overview

Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.




Minimum 15 minutes delayed. Source: LSEG

News Releases

19 Dec '24
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 17,571 shares in Alvotech by ATP Holdings ehf.   Alvotech Investor Relations Benedikt Stefansson, VP 

Recent Events